LAGUNA HILLS, CA, November 07, 2020 – Arthrosi Therapeutics, a clinical-stage biopharmaceutical company focused on developing a best-in-class treatment for gout, has completed a Phase 2a clinical trial for company’s lead asset, AR882. Results from two clinical studies of AR882 conducted at Australia and New Zealand were presented in Annual meeting of American College of Rheumatology Convergence 2020. AR882 demonstrated a strong safety profile, favorable pharmacokinetics, pharmacodynamics, and efficacy outcome in healthy volunteers and in gout patients.
Patients with chronic gout (serum urate (sUA) baseline 9.0 mg/dL) were treated with AR882 50 mg in the phase 2a study, 95% of patients showed sUA levels below 6 mg/dL and 5 mg/dL throughout the entire day. The results indicate that AR882 considerably outperformed the current frontline therapies for gout and has potential to provide clinical benefit in hyperuricemia and gout patients. A phase 2b study for AR882 is being planned. In addition, Arthrosi’s oncology candidate will also start IND enabling studies with plans to submit the US IND at H2 2021.
“Gout has a huge market. In China, there are 200 million hyperuricemia patients and nearly 20 million gout patients while the United States has 120 million hyperuricemia patients and 12 million gout patients,” said Litain Yeh, Arthrosi’s CEO," At Arthrosi, we are committed to the independent development of new drugs to address the unmet medical needs in the treatment for gout. We expect our drug to be the most effective and safe treatment to reduce the frequency of gout attacks and dissolve tophi. Eventually, Arthrosi’s treatment will become the first-line medication for gout treatment.”
“Our leadership team is comprised of key functional experts who have tremendous experience with the FDA’s drug approval process,” continued Dr. Yeh, “We have a range of successful preclinical and clinical trials as well as global approvals already under our belts. The team consists of the core scientists who did the research, management, and development of Lesinurad.
Arthrosi recently completed a series C financing round led by LH Ventures to facilitate the next stage of its clinical trials. Along with other biotech investors, HEDA Ventures participated in this financing round. HEDA Ventures will continue to support Arthrosi’s ongoing efforts to advance the next generation of gout and oncology treatments.
About Arthrosi Therapeutics
Arthrosi is a clinical-stage biopharmaceutical company, developing an oral, best-in-class treatment for gout along with additional pipelines in oncology. Led by experienced management team with extensive expertise in gout and oncology drug development, Arthrosi is developing novel therapies to address unmet medical needs in the treatments of gout, chronic kidney disease and oncology.
Dr. Shunqi Yan, COO
About HEDA Ventures
HEDA is a venture capital firm based in Silicon Valley. HEDA invests in early-stage companies developing differentiated products and services in areas of biotech, healthcare and TMT industries. Leveraging global network and local expertise, HEDA Ventures aims to accelerate enterprise development and business growth.